标题
Cardiorenal benefits of finerenone: protecting kidney and heart
作者
关键词
-
出版物
ANNALS OF MEDICINE
Volume 55, Issue 1, Pages 502-513
出版商
Informa UK Limited
发表日期
2023-01-31
DOI
10.1080/07853890.2023.2171110
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
- (2022) Peter Rossing et al. DIABETES CARE
- SGLT2 inhibitors and finerenone: one or the other or both?
- (2022) Brendon L Neuen et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
- (2022) Lawrence Blonde et al. Endocrine Practice
- Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
- (2022) Ian H. de Boer et al. DIABETES CARE
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- Empagliflozin in Patients with Chronic Kidney Disease
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
- (2021) Marie Pieronne‐Deperrois et al. ESC Heart Failure
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Costs and healthcare utilisation of patients with chronic kidney disease in Spain
- (2021) Carlos Escobar et al. BMC HEALTH SERVICES RESEARCH
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
- (2021) Brendon L Neuen et al. EUROPEAN HEART JOURNAL
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- RICORS2040: the need for collaborative research in chronic kidney disease
- (2021) Alberto Ortiz et al. Clinical Kidney Journal
- Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
- (2021) Gerasimos Filippatos et al. CIRCULATION
- Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- (2021) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
- (2021) Ajay Chaudhuri et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
- (2021) Jonatan Barrera-Chimal et al. Nature Reviews Nephrology
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- (2021) Frank L J Visseren et al. European Journal of Preventive Cardiology
- Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
- (2021) Daiji Kawanami et al. Frontiers in Pharmacology
- Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
- (2021) Peter Rossing et al. Kidney International Reports
- Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Frömter Rats, a Genetic Model of Chronic Kidney Disease
- (2020) Marta Gil-Ortega et al. AMERICAN JOURNAL OF NEPHROLOGY
- The novel non‐steroidal MR antagonist finerenone improves metabolic parameters in high‐fat diet‐fed mice and activates brown adipose tissue via AMPK‐ATGL pathway
- (2020) Vincenzo Marzolla et al. FASEB JOURNAL
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica
- (2020) Sara Erraez et al. NEFROLOGIA
- Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
- (2020) Rajiv Agarwal et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Mineralocorticoid Antagonism and Diabetic Kidney Disease
- (2019) Yuliya Lytvyn et al. Current Diabetes Reports
- Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials
- (2019) Pingping Yang et al. HEART FAILURE REVIEWS
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry
- (2019) Emmanuelle Vidal-Petiot et al. Journal of Clinical Medicine
- Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
- (2018) Radica Z. Alicic et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
- (2018) Marianne Lachaux et al. DIABETES OBESITY & METABOLISM
- The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure
- (2018) Hui Pei et al. MEDICINE
- Mineralocorticoid Receptor and Cardiovascular Disease
- (2018) Mathieu Buonafine et al. AMERICAN JOURNAL OF HYPERTENSION
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
- (2018) Kyle J Foreman et al. LANCET
- Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
- (2018) Raquel González-Blázquez et al. Frontiers in Pharmacology
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature
- (2017) Jennifer J DuPont et al. JOURNAL OF ENDOCRINOLOGY
- Diabetes with early kidney involvement may shorten life expectancy by 16 years
- (2017) Chi Pang Wen et al. KIDNEY INTERNATIONAL
- The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
- (2017) Jochen Dutzmann et al. PLoS One
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
- (2014) L. L. Huang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Características demográficas y clínicas de los pacientes con enfermedad coronaria estable: resultados del registro CLARIFY en España
- (2014) José L. Zamorano et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts
- (2011) Marije van der Velde et al. KIDNEY INTERNATIONAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now